Jasper Therapeutics annual depreciation and amortization
2021
2022
2023
2024
2025
Jasper Therapeutics Depreciation & Amortization Growth & History (JSPR)
Jasper Therapeutics's depreciation and amortization was $1.1M for fiscal 2025.
View full Jasper Therapeutics company overviewJasper Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.1M | −$317,000 | −23.09% |
| 2024 | 2024-12-31 | $1.4M | $265,000 | +23.92% |
| 2023 | 2023-12-31 | $1.1M | $133,000 | +13.64% |
| 2022 | 2022-12-31 | $975,000 | $598,000 | +158.62% |
| 2021 | 2021-12-31 | $377,000 | — | — |
Jasper Therapeutics quarterly depreciation and amortization
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $21,000 | −$237,000 | −91.86% |
| Q1 2026 | 2026-03-31 | $21,000 | −$258,000 | −92.47% |
| Q4 2025 | 2025-12-31 | $290,000 | — | — |
| Q3 2025 | 2025-09-30 | $229,000 | −$271,000 | −54.20% |
| Q2 2025 | 2025-06-30 | $258,000 | −$42,000 | −14.00% |
| Q1 2025 | 2025-03-31 | $279,000 | −$9,000 | −3.13% |
| Q3 2024 | 2024-09-30 | $500,000 | $200,000 | +66.67% |
| Q2 2024 | 2024-06-30 | $300,000 | $0 | 0.00% |
| Q1 2024 | 2024-03-31 | $288,000 | $14,000 | +5.11% |
| Q3 2023 | 2023-09-30 | $300,000 | $0 | 0.00% |
| Q2 2023 | 2023-06-30 | $300,000 | $82,000 | +37.61% |
| Q1 2023 | 2023-03-31 | $274,000 | $58,000 | +26.85% |
| Q3 2022 | 2022-09-30 | $300,000 | $168,000 | +127.27% |
| Q2 2022 | 2022-06-30 | $218,000 | $189,000 | +651.72% |
| Q1 2022 | 2022-03-31 | $216,000 | $194,000 | +881.82% |
| Q3 2021 | 2021-09-30 | $132,000 | — | — |
| Q2 2021 | 2021-06-30 | $29,000 | — | — |
| Q1 2021 | 2021-03-31 | $22,000 | — | — |
Jasper Therapeutics depreciation and amortization trends
Between the periods ended 2021-12-31 and 2025-12-31, Jasper Therapeutics's depreciation and amortization increased from $377,000 to $1.1M, a change of $679,000. The latest reported quarter, Q2 2026, shows $21,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Jasper Therapeutics source filings ↗